



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/190499/2021

European Medicines Agency decision P/0201/2021

of 10 May 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 (EMA-002915-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0201/2021

of 10 May 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 (EMA-002915-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Sanofi Pasteur on 19 November 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 March 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03, solution and emulsion for emulsion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03, solution and emulsion for emulsion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Sanofi Pasteur, 14 Espace Henry Vallée, 69007 – Lyon, France.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/65552/2021
Amsterdam, 26 March 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002915-PIP01-20

Scope of the application

Active substance(s):

SARS-CoV2 prefusion spike delta TM (CoV-2 preS dTM) adjuvanted with AS03

Condition(s):

Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Solution and emulsion for emulsion for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Sanofi Pasteur

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sanofi Pasteur submitted for agreement to the European Medicines Agency on 19 November 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 January 2021.

Supplementary information was provided by the applicant on 15 February 2021. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Prevention of coronavirus disease 2019 (COVID-19)

2.1.1. Indication(s) targeted by the PIP

Prevention of coronavirus disease 2019 (COVID-19)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution and emulsion for emulsion for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 1 (VAT00003) Randomised, modified double-blind, controlled immunogenicity and safety study of SARS-CoV2 prefusion spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 versus active vaccine comparator or placebo in children from birth to less than 18 years of age. Study 2 (VAT00009) Open label, uncontrolled, safety and immunogenicity study of SARS-CoV2 prefusion spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 in immunocompromised paediatric participants from birth to less than 18 years of age
Extrapolation, modelling and	0	Not applicable.

Area	Number of measures	Description
simulation studies		
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes